Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pentosan Polysulfate Sodium
Therapeutic Area: Musculoskeletal Product Name: Zilosul
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
Positive feedback has been received from European Medicines Agency after Paradigm’s recent Scientific Advice meeting, a key regulatory milestone which supports and validates the company’s clinical development and commercialisation plans for Zilosul® in Europe.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pentosan Polysulfate Sodium
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Bell Potter Securities
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 20, 2020
Details:
Proceeds will be applied to costs of the second phase 3 osteoarthritis (OA) clinical trial and leaves Paradigm fully-funded through to completion of this trial.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
